Germany · Investor

Boehringer Ingelheim Venture Fund

Last cheque observed Sep 2026; 59 cheques on record.

Deploying nowCorporate VC

Pre-seedSeedSeries ACell TherapyMedicineLife-science

Deploying now
60%of best year6cheques in 12 months, 59 on record
Since the last cheque53days00hrs00min00sec
Median round$20MRounds led5 of 59Sole investor7 roundsExits1 from the portfolioMostly inGermany, 34%
Pitch Boehringer Ingelheim Venture Fund

Boehringer Ingelheim Venture Fund highlights

  1. 01

    6 cheques in the last 12 months

  2. 02

    Mostly Series A and Seed: 55% of its rounds

  3. 03

    Sole investor in 7 rounds, median $10M

  4. 04

    1 exits from the portfolio

What they do

Type
Corporate VC (from a list, unverified)
Cheque size
Not stated
Stages
Pre-seedSeedSeries ASeries BGrowth
Sectors
Cell TherapyMedicineLife-science
Based in
Ingelheim Am Rhein, Germany
Cold pitches
Not stated

The record

Every round we can evidence, newest first59 appearances

  1. 2026

    6 rounds

  2. Sept
    Cloverleaf BioSeed · 4BIO Capital$33MWith 4 others
  3. Jun
    smartbaxVenture · DEUndisclosedWith 1 other
  4. Apr
    TacalyxSeed · DE$13MWith 3 others
  5. Feb
    Centauri TherapeuticsSeries A · GB$8.1MWith 2 others
  6. Jan
    TECregenSeed · CH · Ventureburn$13MLed
  7. Jan
    STRM.BIOSeed · US$8.0MSole investor
  8. 2025

    8 rounds

  9. Oct
    smartbaxSeed · DE$5.5MWith 1 other
  10. Aug
    WellthSeries C · US · Comcast Ventures$36MWith 8 others
  11. Jul
    EvlaBioSeed · CH$25MWith 1 other
  12. Jun
    ArrePathVenture · USUndisclosedWith 1 other
  13. May
    NuevocorSeries B · SG$45MWith 3 others
  14. Apr
    HepaRegeniXVenture · DE$24MWith 2 others
  15. Mar
    BrainomixSeries C · GB$18MWith 4 others
  16. Jan
    Glox TherapeuticsGrant · GB$617KWith 1 other
  17. 2024

    6 rounds

  18. Dec
    Refoxy PharmaSeed · DE$9.6MWith 1 other
  19. Oct
    AignosticsSeries B · DE$34MWith 3 others
  20. Aug
    ImCheck TherapeuticsGrant · FR$22MWith 6 others
  21. Jun
    TacalyxSeed · DE$7.5MWith 2 others
  22. Mar
    Asgard TherapeuticsSeries A · SE$33MWith 2 others
  23. Jan
    Acousia TherapeuticsVenture · DEUndisclosedSole investor
  24. 2023

    6 rounds

  25. Dec
    xCuresVenture · USUndisclosedWith 2 others
  26. Oct
    Actym Therapeutics, Inc.Series A · US$26MWith 2 others
  27. May
    DiogenXSeries A · FR$37MWith 2 others
  28. Apr
    T3 PharmaceuticalsVenture · CHUndisclosedWith 1 other
  29. Jan
    C-mo Medical SolutionsSeed · PT$760KWith 1 other
  30. Jan
    Rewind TherapeuticsVenture · BEUndisclosedSole investor
  31. 2022

    4 rounds

  32. Dec
    Ruipeng Pet HealthcareVentureUndisclosedWith 4 others
  33. Aug
    etherna immunotherapiesSeries B · BE$39MWith 3 others
  34. May
    PerfoodVenture · DEUndisclosedWith 1 other
  35. Jan
    Optina DiagnosticsSeries A · CA$2.1MWith 4 others
  36. 2021

    4 rounds

  37. Dec
    OncoMyx TherapeuticsSeries B · US$50MWith 2 others
  38. Jul
    DopavisionSeries A · DE$14MWith 2 others
  39. May
    Rinri TherapeuticsGrant$4.5MWith 2 others
  40. Mar
    Delonix BioworksSeed$14MWith 2 others
  41. 2020

    3 rounds

  42. Sept
    Libra TherapeuticsSeries A$29MSole investor
  43. Aug
    BodyportSeries A$11MWith 4 others
  44. Jan
    NBE-TherapeuticsSeries C$22MWith 1 other
  45. 2019

    6 rounds

  46. Dec
    ImCheck TherapeuticsSeries B · FR · FinSMEs$53MWith 9 others
  47. Dec
    MetabomedSeries B$13MSole investor
  48. Oct
    Abalos TechnologiesSeries A · DE · FinSMEs$13MLed

An announcement gives the size of the round, not the size of this investor's cheque: the only rounds that imply a cheque are those where they were the sole named investor.

The team

We hold 13 people at this firm from the lists this database was built from: a weaker source than the filings, since a list does not say when a title ended. Login to see them.

Exits from the portfolio

Companies it backed that were later bought or listed1 in all

OkairosBought by GlaxoSmithKline$325MMay 2013

An exit counts when it came after the firm's first round in the company. From historical deal records.

Who they invest alongside

The investors most often in the same rounds as Boehringer Ingelheim Venture Fund. A count of rooms they were both in, not a relationship either has claimed.

Recently backed

The latest companies Boehringer Ingelheim Venture Fund put money into.

Quick answers about Boehringer Ingelheim Venture Fund

What does Boehringer Ingelheim Venture Fund invest in?

Boehringer Ingelheim Venture Fund invests most often at Series A and Seed (55% of the rounds on record), in sectors such as Cell Therapy, Medicine and Life-science.

How active is Boehringer Ingelheim Venture Fund?

59 investments on record, 6 of them in the last 12 months, and it led 5. The most recent was in Sept 2026.

What has Boehringer Ingelheim Venture Fund invested in recently?

Its most recent investments on record: Cloverleaf Bio (Seed, Sept 2026), smartbax (Venture, Jun 2026) and Tacalyx (Seed, Apr 2026).

How big are Boehringer Ingelheim Venture Fund's cheques?

The median round it joins is $20M.

Does Boehringer Ingelheim Venture Fund lead rounds?

Sometimes: it led 5 of its 59 investments on record (8%).

Where does Boehringer Ingelheim Venture Fund invest?

Most of the companies it backs are in Germany (34%), the United States (19%) and the United Kingdom (9%).

Is Boehringer Ingelheim Venture Fund investing now?

Yes: it is actively investing, with 6 investments in the last 12 months.

Who does Boehringer Ingelheim Venture Fund invest alongside?

Most often KurmaPartners (9 rounds together), Wellington Partners (7 rounds together) and Idinvest Partners (5 rounds together).

Raising now?

Find the investors who back rounds like yours, and keep every conversation on one fundraising board.

Built from the rounds we watched, its filings and its own website, refreshed every night. How we count · Report a correction · Is this your firm? Claim it